Celia Oreja-Guevara

List of Publications by Year
in descending order

144	7,071	71102 41	66911 78
papers	citations	h-index	g-index

167	167	167	7216
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
2	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	10.2	397
3	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
4	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology, The, 2016, 15, 574-584.	10.2	266
5	Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. CNS Drugs, 2014, 28, 147-156.	5.9	254
6	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238
7	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	2.5	166
8	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	7.6	162
9	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 739-746.	3.0	148
10	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	5.3	143
11	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	7.6	140
12	Neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e225.	6.0	134
13	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS ONE, 2015, 10, e0122686.	2.5	122
14	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8463-8470.	7.1	112
15	TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurology, 2012, 12, 95.	1.8	108
16	Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 578.	4.5	103
17	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101
18	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2018, 19, 153-160.	2.0	101

#	Article	IF	Citations
19	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100
20	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
21	The international European Academy of Neurology survey on neurological symptoms in patients with COVIDâ€19 infection. European Journal of Neurology, 2020, 27, 1727-1737.	3.3	90
22	Biomarkers in Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a029058.	6.2	88
23	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2015, 4, 202-218.	2.0	85
24	Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1347-1355.	3.0	81
25	Therapeutic Decisions in Multiple Sclerosis. JAMA Neurology, 2013, 70, 1315-24.	9.0	80
26	Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Therapeutic Advances in Neurological Disorders, 2011, 4, 139-168.	3.5	76
27	Spasticity in multiple sclerosis: results of a patient survey. International Journal of Neuroscience, 2013, 123, 400-408.	1.6	75
28	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	3.0	73
29	Cognitive Dysfunctions and Assessments in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 581.	2.4	70
30	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Annals of Neurology, 2014, 76, 880-890.	5.3	67
31	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
32	Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study. BMC Neurology, 2015, 15, 243.	1.8	58
33	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	3.7	57
34	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. CNS Drugs, 2017, 31, 33-50.	5.9	57
35	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis Journal, 2012, 18, 974-982.	3.0	56
36	Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098.	5.3	55

#	Article	IF	Citations
37	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
38	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
39	Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. European Journal of Paediatric Neurology, 2013, 17, 50-54.	1.6	45
40	Treatment with Natalizumab in Relapsingâ€“Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism. Journal of Clinical Immunology, 2011, 31, 623-631.	3.8	44
41	Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging. Frontiers in Neurology, 2016, 7, 53.	2.4	44
42	Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2015, 2, 479-491.	3.7	43
43	Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. Journal of Neurology, 2012, 259, 1814-1823.	3.6	42
44	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	41
45	Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation. Frontiers in Neurology, 2017, 8, 643.	2.4	40
46	Optical Coherence Tomography in Multiple Sclerosis and Neuromyelitis Optica: An Update. Multiple Sclerosis International, 2011, 2011, 1-11.	0.8	39
47	Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Review of Neurotherapeutics, 2013, 13, 55-59.	2.8	39
48	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
49	The Kurtzke EDSS rank stability increases 4â€…years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	1.9	37
50	New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain. Multiple Sclerosis Journal, 2017, 23, 166-178.	3.0	37
51	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
52	Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Multiple Sclerosis and Related Disorders, 2019, 32, 54-63.	2.0	37
53	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	3.0	36
54	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.6	35

#	Article	IF	Citations
55	Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 916-927.	6.4	35
56	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
57	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	2.5	35
58	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	3.0	34
59	Magnetization Transfer Magnetic Resonance Imaging and Clinical Changes in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2006, 63, 736.	4.5	33
60	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 2015, 22, 981-989.	3.3	32
61	Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain and Behavior, 2017, 7, e00671.	2.2	32
62	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Multiple Sclerosis Journal, 2022, 28, 480-486.	3.0	32
63	Analysis of lymphocyte subpopulations in cerebrospinal fluid and peripheral blood in patients with multiple sclerosis and inflammatory diseases of the nervous system. Acta Neurologica Scandinavica, 1998, 98, 310-313.	2.1	30
64	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
65	The role of V5 (hMT+) in visually guided hand movements: an fMRI study. European Journal of Neuroscience, 2004, 19, 3113-3120.	2.6	29
66	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
67	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. Journal of Neurology, 2013, 260, 462-469.	3.6	27
68	EAN consensus statement for management of patients with neurological diseases during the COVIDâ€19 pandemic. European Journal of Neurology, 2021, 28, 7-14.	3.3	27
69	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PLoS ONE, 2013, 8, e63480.	2.5	26
70	Vitamina D y remielinizaciÃ³n en la esclerosis mÃºltiple. NeurologÃa, 2018, 33, 177-186.	0.7	26
71	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. Neurology, 2018, 91, e249-e257.	1.1	26
72	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Multiple Sclerosis and Related Disorders, 2021, 47, 102641.	2.0	26

#	Article	IF	Citations
73	Risk and outcomes of COVIDâ€19 in patients with multiple sclerosis. European Journal of Neurology, 2021, 28, 3712-3721.	3.3	26
74	Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. Journal of Immunological Methods, 2011, 371, 170-173.	1.4	25
75	Plasticity of cortical hand muscle representation in patients with hemifacial spasm. Neuroscience Letters, 1999, 272, 33-36.	2.1	24
76	Clinical efficacy and effectiveness of Sativex^{Â®}, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics, 2012, 12, 3-8.	2.8	24
77	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
78	A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain-BarrÃ© syndrome. Journal of the Neurological Sciences, 1997, 151, 29-34.	0.6	23
79	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. Multiple Sclerosis Journal, 2019, 25, 352-360.	3.0	22
80	A call for a global COVID-19 Neuro Research Coalition. Lancet Neurology, The, 2020, 19, 482-484.	10.2	22
81	Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. Journal of Neurology, 2020, 267, 2362-2371.	3.6	21
82	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
83	Clinically Isolated Syndromes Suggestive of Multiple Sclerosis: An Optical Coherence Tomography Study. PLoS ONE, 2012, 7, e33907.	2.5	20
84	Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 321-333.	1.4	20
85	Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. Advances in Therapy, 2019, 36, 3238-3252.	2.9	20
86	Improving patient–physician dialog: commentary on the results of the MS Choices survey. Patient Preference and Adherence, 2012, 6, 143.	1.8	19
87	Documento del Grupo de Consenso de la Sociedad EspaÃ±ola de NeurologÃa sobre el uso de medicamentos en esclerosis mÃºltiple. NeurologÃa, 2013, 28, 375-378.	0.7	18
88	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	3.0	18
89	Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges. Frontiers in Cellular Neuroscience, 2019, 13, 107.	3.7	18
90	Overview of magnetic resonance imaging for management of relapsingâ”remitting multiple sclerosis in everyday practice. European Journal of Neurology, 2015, 22, 22-27.	3.3	17

#	Article	IF	Citations
91	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Frontiers in Neurology, 2019, 10, 253.	2.4	17
92	Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641880324.	3.5	16
93	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
94	Efficacy and safety of ocrelizumab in patients with relapsingâ€remitting multiple sclerosis with suboptimal response to prior diseaseâ€modifying therapies: A primary analysis from the phase 3b CASTING singleâ€arm, openâ€label trial. European Journal of Neurology, 2022, 29, 790-801.	3.3	15
95	A plea for equitable global access to COVIDâ€19 diagnostics, vaccination and therapy: The NeuroCOVIDâ€19 Task Force of the European Academy of Neurology. European Journal of Neurology, 2021, 28, 3849-3855.	3.3	14
96	Consenso espaÃ±ol actualizado sobre el uso del natalizumab (TysabriÂ®)-2013. NeurologÃa, 2015, 30, 302-314.	0.7	13
97	Primary prevention of COVIDâ€19: Advocacy for vaccination from a neurological perspective. European Journal of Neurology, 2021, 28, 3226-3229.	3.3	13
98	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	3.0	13
99	Vitamin D and remyelination in multiple sclerosis. NeurologÃa (English Edition), 2018, 33, 177-186.	0.4	12
100	Familial multiple sclerosis and association with other autoimmune diseases. Brain and Behavior, 2018, 8, e00899.	2.2	11
101	Neuritis Ã³ptica asociada o no a esclerosis mÃºltiple: estudio estructural y funcional. NeurologÃa, 2010, 25, 78-82.	0.7	10
102	Intervenciones psicoterapÃ©uticas y psicosociales para el manejo del estrÃ©s en esclerosis mÃºltiple: aportaciÃ³n de intervenciones basadas en mindfulness. NeurologÃa, 2016, 31, 113-120.	0.7	10
103	Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). Multiple Sclerosis and Related Disorders, 2019, 29, 7-14.	2.0	10
104	Single-subject structural cortical networks in clinically isolated syndrome. Multiple Sclerosis Journal, 2020, 26, 1392-1401.	3.0	10
105	Outcome of patients with amyotrophic lateral sclerosis attending in a multidisciplinary care unit. NeurologÃa (English Edition), 2011, 26, 455-460.	0.4	9
106	Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. Journal of Neurology, 2013, 260, 1258-1262.	3.6	9
107	Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. Therapeutic Advances in Neurological Disorders, 2014, 7, 137-149.	3.5	9
108	Analysis of the Relationship between the Month of Birth and Risk of Multiple Sclerosis in a Spanish Population. European Neurology, 2016, 76, 202-209.	1.4	9

#	Article	IF	Citations
109	Multimarker risk stratification approach at multiple sclerosis onset. Clinical Immunology, 2017, 181, 43-50.	3.2	9
110	Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. PLoS ONE, 2020, 15, e0230846.	2.5	9
111	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582.	3.5	9
112	Consensus statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases. NeurologÃa (English Edition), 2013, 28, 375-378.	0.4	8
113	Effects of diazoxide in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e147.	6.0	8
114	Inhibition of neurogenesis in a case of Marburg variant multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 71-76.	2.0	8
115	Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders, 2020, 43, 102158.	2.0	8
116	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research, 2021, 23, e29558.	4.3	8
117	Consenso espaÃ±ol sobre la utilizaciÃ³n de natalizumab (TysabriÂ®) - 2011. NeurologÃa, 2012, 27, 432-441.	0.7	7
118	Pittsburgh compound B and other amyloid positron emission tomography tracers for the study of white matter and multiple sclerosis. Annals of Neurology, 2016, 80, 166-166.	5.3	7
119	Amyloid PET in pseudotumoral multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 15, 15-17.	2.0	7
120	Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2151-2153.	3.0	7
121	Spanish consensus on the use of natalizumab (TysabriÂ®)-2013. NeurologÃa (English Edition), 2015, 30, 302-314.	0.4	6
122	Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: The contribution of mindfulness-based interventions. NeurologÃa (English Edition), 2016, 31, 113-120.	0.4	6
123	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
124	Clinical pathways for the care of multiple sclerosis patients. NeurologÃa (English Edition), 2010, 25, 156-162.	0.4	5
125	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	1.0	5
126	Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. PLoS ONE, 2021, 16, e0258437.	2.5	5

#	Article	IF	Citations
127	Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe. Expert Review of Neurotherapeutics, 2013, 13, 61-66.	2.8	4
128	Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 59, 103669.	2.0	4
129	DiseÃ±o de una vÃa clÃnica para la atenciÃ³n a los pacientes con esclerosis mÃºltiple. NeurologÃa, 2010, 25, 156-162.	0.7	3
130	Optic neuritis, multiple sclerosis-related or not: Structural and functional study. NeurologÃa (English Edition), 2010, 25, 78-82.	0.4	3
131	Spanish consensus on the use of natalizumab (TysabriÂ®) â€“ 2011. NeurologÃa (English Edition), 2012, 27, 432-441.	0.4	3
132	Consenso de expertos sobre el uso de alemtuzumab en la prÃ¡ctica clÃnica diaria en EspaÃ±a. NeurologÃa, 2022, 37, 615-630.	0.7	3
133	Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. NeurologÃa (English Edition), 2022, 37, 615-630.	0.4	3
134	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
135	EXPOSURE TO INTERFERON-Î² THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A17.2-A17.	1.9	2
136	RevisiÃ³n sistemÃ¡tica sobre la eficacia y seguridad de los neuroestimuladores perifÃ©ricos del ganglio esfenopalatino para el tratamiento de la cefalea crÃ³nica en racimos refractaria. NeurologÃa, 2018, 36, 440-440.	0.7	2
137	Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). Multiple Sclerosis Journal, 2020, 26, 859-868.	3.0	2
138	Family planning is the second most relevant factor for treatment decisions after disease activity â€“ No. Multiple Sclerosis Journal, 2020, 26, 642-643.	3.0	2
139	Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Revista De Neurologia, 2016, 62, 559-69.	7.8	2
140	Monitoring neuromyelitis optica activity. Expert Review of Neurotherapeutics, 2013, 13, 989-999.	2.8	1
141	PND65 Spanish Neurology Therapeutic Society Guidelines for the Treatment of Relapsing Remitting MS: Are They Followed by Spanish Neurologists?. Value in Health, 2012, 15, A557.	0.3	0
142	004â€¦Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
143	Natural history and optic neuritis in multiple sclerosis. Anales De PediatrÃa (English Edition), 2022, 96, 66-68.	0.2	0
144	038â€… Pregnancy outcomes in patients treated with ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A25.2-A25.	1.9	0